Anavex Life Sciences Corp. financial data

Symbol
AVXL on Nasdaq
Location
630 5 Th Avenue, 20 Th Floor, New York, NY
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 13.6 % +58.8%
Return On Equity -45.7 % -49.1%
Return On Assets -40.2 % -42.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 85.9M shares +1.3%
Common Stock, Shares, Outstanding 85.4M shares +0.73%
Entity Public Float 412M USD -38.2%
Common Stock, Value, Issued 85K USD 0%
Weighted Average Number of Shares Outstanding, Basic 85.4M shares +1%
Weighted Average Number of Shares Outstanding, Diluted 85.4M shares +1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 41.9M USD +4.04%
General and Administrative Expense 12.9M USD +17.8%
Operating Income (Loss) -54.8M USD -6.99%
Nonoperating Income (Expense) 6.67M USD -31%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43M USD +9.47%
Net Income (Loss) Attributable to Parent -48.2M USD -16%
Earnings Per Share, Basic 0 USD/shares -14%
Earnings Per Share, Diluted 0 USD/shares -14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 101M USD -27.1%
Assets 102M USD -27.6%
Accounts Payable, Current 6.74M USD +92.4%
Accrued Liabilities, Current 3.93M USD -46.4%
Liabilities 11.5M USD -2.38%
Retained Earnings (Accumulated Deficit) -373M USD -14.8%
Stockholders' Equity Attributable to Parent 91M USD -29.9%
Liabilities and Equity 102M USD -27.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1M USD -65.6%
Net Cash Provided by (Used in) Financing Activities 708K USD +1100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 85.4M shares +0.73%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 101M USD -27.1%
Deferred Tax Assets, Valuation Allowance 92.2M USD +19.5%
Deferred Tax Assets, Gross 15.1M USD +110%
Deferred Tax Assets, Operating Loss Carryforwards 48.1M USD +3.6%
Current Income Tax Expense (Benefit) 59K USD -79%
Preferred Stock, Shares Authorized 10M shares 0%
Share-based Payment Arrangement, Expense 8.2M USD -53.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%